[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.185.157. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1977

Memory Enhancement After Physostigmine Treatment in the Amnesic Syndrome

Author Affiliations

From the Departments of Neurology (Dr Peters) and Neurosurgery (Dr Levin) and the Marine Biomedical Institute (Dr Peters), the University of Texas Medical Branch, Galveston, Tex.

Arch Neurol. 1977;34(4):215-219. doi:10.1001/archneur.1977.00500160029004
Abstract

• Central anticholinergic agents (eg, scopolamine) are known to produce transient memory deficits in human and animal subjects. Damage to the limbic system frequently results from herpes simplex encephalitis (HSE) and produces a memory deficit. If this deficit is due to limbic cholinergic pathway destruction, it might improve with central cholinergic agonists (eg, physostigmine). In a double-blind study over a three-week period, we compared memory performance on three days after 0.8-mg subcutaneous physostigmine therapy (three sessions) to baseline performance and that obtained in three randomly interspersed control sessions. Serial assessment of memory by the Selective Reminding Test showed reproducible enhancement of long-term storage and retrieval with physostigmine treatment. Performance after control injections did not exceed baseline levels. Our findings encourage the hypothesis that cholinergic mechanisms subserve memory and that their pharmacological potentiation might favorably influence some amnesic conditions.

×